This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ali A. Global health: epilepsy. Semin Neurol. 2018;38:191–9.
Carcak N, Ozkara C. Seizures and antiepileptic drugs: from pathophysiology to clinical practice. Curr Pharm Des. 2017;23:6376–88.
Eskioglou E, Perrenoud MP, Ryvlin P, Novy J. Novel treatment and new drugs in epilepsy treatment. Curr Pharm Des. 2017;23:6389–98.
Loscher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72:606–38.
McTague A, Howell KB, Cross JH, Kurian MA, Scheffer IE. The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol. 2016;15:304–16.
Specchio N, Curatolo P. Developmental and epileptic encephalopathies: what we do and do not know. Brain. 2021;144:32–43.
Abraham AA, Tisdale JF. Gene therapy for sickle cell disease: moving from the bench to the bedside. Blood. 2021;138:932–41.
Leebeek FWG, Miesbach W. Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. 2021;138:923–31.
Lin FL, Wang PY, Chuang YF, Wang JH, Wong VHY, Bui BV, et al. Gene therapy intervention in neovascular eye disease: a recent update. Mol Ther. 2020;28:2120–38.
Apte RS. Gene therapy for retinal degeneration. Cell. 2018;173:5.
Colasante G, Qiu Y, Massimino L, Di Berardino C, Cornford JH, Snowball A, et al. In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy. Brain. 2020;143:891–905.
Colasante G, Lignani G, Brusco S, Di Berardino C, Carpenter J, Giannelli S, et al. dCas9-based Scn1a gene activation restores inhibitory interneuron excitability and attenuates seizures in Dravet syndrome mice. Mol Ther. 2020;28:235–53.
Tian F, Cao B, Xu H, Zhan L, Nan F, Li N, et al. Epilepsy phenotype and response to KCNQ openers in mice harboring the Kcnq2 R207W voltage-sensor mutation. Neurobiol Dis. 2022;174:105860.
Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149–57.
Huang TP, Zhao KT, Miller SM, Gaudelli NM, Oakes BL, Fellmann C, et al. Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors. Nat Biotechnol. 2019;37:626–31.
Yao X, Wang X, Hu X, Liu Z, Liu J, Zhou H, et al. Homology-mediated end joining-based targeted integration using CRISPR/Cas9. Cell Res. 2017;27:801–14.
Blumkin L, Suls A, Deconinck T, De Jonghe P, Linder I, Kivity S, et al. Neonatal seizures associated with a severe neonatal myoclonus like dyskinesia due to a familial KCNQ2 gene mutation. Eur J Paediatr Neurol. 2012;16:356–60.
Dedek K, Kunath B, Kananura C, Reuner U, Jentsch TJ, Steinlein OK. Myokymia and neonatal epilepsy caused by a mutation in the voltage sensor of the KCNQ2 K+ channel. Proc Natl Acad Sci USA. 2001;98:12272–7.
Liu Y, Yang G, Huang S, Li X, Wang X, Li G, et al. Enhancing prime editing by Csy4-mediated processing of pegRNA. Cell Res. 2021;31:1134–6.
Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol. 2015;33:985–9.
Finn JD, Smith AR, Patel MC, Shaw L, Youniss MR, van Heteren J, et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 2018;22:2227–35.
Acknowledgements
We thank Dr. Hui Yang for his insightful comments on this study. We thank Pei Wang, Yong-jie Cai, Jun-jie Tang, De-lun Kong for help in experiment on this study. This study was supported by the High-level new R&D institute (2019B090904008) and the High-level Innovative Research Institute (2021B0909050003) of the Department of Science and Technology of Guangdong Province, the National Science Fund for Distinguished Young Scholars (81825021), and National Science and Technology Innovation 2030 Major Program (2021ZD0200900). The diagrams were created with Biorender.com.
Author information
Authors and Affiliations
Contributions
BRC and FYT designed and performed experiments. YMH and YDS performed data analysis. JHL, CLX and RML performed PCR analysis and FACS. YW and JKL performed the zygote injection. QBG, HYX and LZ performed the open field test, 6-HZ and PTZ test. BRC, FYT, ZBG, YDS and CYZ wrote the paper. YDS, XDH, ZBG and CYZ supervised the project.
Corresponding authors
Ethics declarations
Competing interests
Yu Wei and Ji-kai Liu are employees of the Shanghai Immunocan Biotech Co., LTD. The other authors disclose no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Cao, Br., Huang, Ym., Tian, Fy. et al. Prime editing-based gene correction alleviates the hyperexcitable phenotype and seizures of a genetic epilepsy mouse model. Acta Pharmacol Sin 44, 2342–2345 (2023). https://doi.org/10.1038/s41401-023-01115-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41401-023-01115-5